Research indicates that marrying nanocatalytic sensitizers with Amyloid Precursor Protein/Death Receptor 6 Inhibitor 12 can surmount the resistance of NSCLC to osimertinib via the ferroptosis pathway and may thwart its metastasis (66). The gene discussed is APP; the disease is non-small cell lung carcinoma.